Moleculin Biotech, Inc. Research and Development Expense
Moleculin Biotech, Inc. (MBRX) reported Research and Development Expense of $5.45 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- Moleculin Biotech, Inc. research and development expense for the quarter ending 2026-06-30 was $5.45M, a 51.39% increase year-over-year.
- Moleculin Biotech, Inc. research and development expense for the quarter ending 2026-03-31 was $5.38M, a 56.56% increase year-over-year.
- Moleculin Biotech, Inc. research and development expense for the quarter ending 2025-12-31 was $5.12M, a 14.86% increase year-over-year.
- Moleculin Biotech, Inc. research and development expense for the quarter ending 2025-09-30 was $3.74M, a 24.21% decline year-over-year.
- Moleculin Biotech, Inc. research and development expense for fiscal 2025 was $15.89M, a 10.37% decline from fiscal 2024.
- Moleculin Biotech, Inc. research and development expense for fiscal 2024 was $17.73M, a 9.02% decline from fiscal 2023.
- Moleculin Biotech, Inc. research and development expense for fiscal 2023 was $19.49M, a 2.74% increase from fiscal 2022.
- Moleculin Biotech, Inc. research and development expense for fiscal 2022 was $18.97M, a 31.56% increase from fiscal 2021.
| Period end | Research and Development Expense 2 month | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 5 month | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $5.45M 10-Q · filed 2026-08-13 | $10.83M 10-Q · filed 2026-08-13 | $15.95M derived: sum of 3 quarters · filed 2026-08-13 | $19.68M derived: sum of 4 quarters · filed 2026-08-13 | ||||||
| 2026-03-31 | $5.38M 10-Q · filed 2026-05-14 | $10.49M derived: sum of 2 quarters · filed 2026-05-14 | $14.23M derived: sum of 3 quarters · filed 2026-05-14 | $17.83M derived: sum of 4 quarters · filed 2026-08-13 | ||||||
| 2025-12-31 | $5.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $8.86M derived: sum of 2 quarters · filed 2026-03-18 | $12.46M derived: sum of 3 quarters · filed 2026-08-13 | $15.89M 10-K · filed 2026-03-18 | ||||||
| 2025-09-30 | $3.74M 10-Q · filed 2025-11-13 | $7.34M derived: sum of 2 quarters · filed 2026-08-13 | $10.77M 10-Q · filed 2025-11-13 | $15.23M derived: sum of 4 quarters · filed 2026-08-13 | ||||||
| 2025-06-30 | $3.60M 10-Q · filed 2026-08-13 | $7.04M 10-Q · filed 2026-08-13 | $11.49M derived: sum of 3 quarters · filed 2026-08-13 | $16.42M derived: sum of 4 quarters · filed 2026-08-13 | ||||||
| 2025-03-31 | $3.44M 10-Q · filed 2026-05-14 | $7.89M derived: sum of 2 quarters · filed 2026-05-14 | $12.82M derived: sum of 3 quarters · filed 2026-05-14 | $16.91M derived: sum of 4 quarters · filed 2026-05-14 | ||||||
| 2024-12-31 | $4.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $9.39M derived: sum of 2 quarters · filed 2026-03-18 | $13.48M derived: sum of 3 quarters · filed 2026-03-18 | $17.73M 10-K · filed 2026-03-18 | ||||||
| 2024-09-30 | $4.93M 10-Q · filed 2025-11-13 | $9.02M derived: sum of 2 quarters · filed 2025-11-13 | $13.27M 10-Q · filed 2025-11-13 | $19.91M derived: sum of 4 quarters · filed 2025-11-13 | ||||||
| 2024-06-30 | $4.09M 10-Q · filed 2025-08-12 | $8.34M 10-Q · filed 2025-08-12 | $14.97M derived: sum of 3 quarters · filed 2025-08-12 | $18.25M derived: sum of 4 quarters · filed 2025-08-12 | ||||||
| 2024-03-31 | $4.25M 10-Q · filed 2025-05-13 | $10.88M derived: sum of 2 quarters · filed 2025-05-13 | $14.16M derived: sum of 3 quarters · filed 2025-05-13 | $18.05M derived: sum of 4 quarters · filed 2025-05-13 | ||||||
| 2023-12-31 | $6.63M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $9.91M derived: sum of 2 quarters · filed 2025-03-21 | $13.80M derived: sum of 3 quarters · filed 2025-03-21 | $19.49M 10-K · filed 2025-03-21 | ||||||
| 2023-09-30 | $3.28M 10-Q · filed 2024-11-08 | $7.17M derived: sum of 2 quarters · filed 2024-11-08 | $12.86M 10-Q · filed 2024-11-08 | $17.03M derived: sum of 4 quarters · filed 2024-11-08 | ||||||
| 2023-06-30 | $3.89M 10-Q · filed 2024-08-13 | $9.58M 10-Q · filed 2024-08-13 | $13.75M derived: sum of 3 quarters · filed 2024-08-13 | $19.72M derived: sum of 4 quarters · filed 2024-08-13 | ||||||
| 2023-03-31 | $5.69M 10-Q · filed 2024-05-10 | $9.87M derived: sum of 2 quarters · filed 2024-05-10 | $15.83M derived: sum of 3 quarters · filed 2024-05-10 | $20.03M derived: sum of 4 quarters · filed 2024-05-10 | ||||||
| 2022-12-31 | $4.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $10.14M derived: sum of 2 quarters · filed 2024-03-22 | $14.35M derived: sum of 3 quarters · filed 2024-03-22 | $18.97M 10-K · filed 2024-03-22 | ||||||
| 2022-09-30 | $5.96M 10-Q · filed 2023-11-13 | $10.17M derived: sum of 2 quarters · filed 2023-11-13 | $14.79M 10-Q · filed 2023-11-13 | $17.97M derived: sum of 4 quarters · filed 2023-11-13 | ||||||
| 2022-06-30 | $4.20M 10-Q · filed 2023-08-10 | $8.82M 10-Q · filed 2023-08-10 | $12.00M derived: sum of 3 quarters · filed 2023-08-10 | $16.10M derived: sum of 4 quarters · filed 2023-08-10 | ||||||
| 2022-03-31 | $4.62M 10-Q · filed 2023-05-10 | $7.80M derived: sum of 2 quarters · filed 2023-05-10 | $11.89M derived: sum of 3 quarters · filed 2023-05-10 | $14.93M derived: sum of 4 quarters · filed 2023-05-10 | ||||||
| 2021-12-31 | $3.18M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $7.27M derived: sum of 2 quarters · filed 2023-03-22 | $10.31M derived: sum of 3 quarters · filed 2023-03-22 | $14.42M 10-K · filed 2023-03-22 | ||||||
| 2021-09-30 | $4.09M 10-Q · filed 2022-11-10 | $7.13M derived: sum of 2 quarters · filed 2022-11-10 | $11.24M 10-Q · filed 2022-11-10 | $13.03M derived: sum of 4 quarters · filed 2022-11-10 | ||||||
| 2021-06-30 | $3.04M 10-Q · filed 2022-08-12 | $7.14M 10-Q · filed 2022-08-12 | $8.93M derived: sum of 3 quarters · filed 2022-08-12 | $13.37M derived: sum of 4 quarters · filed 2022-08-12 | ||||||
| 2021-03-31 | $4.11M 10-Q · filed 2022-05-11 | $5.89M derived: sum of 2 quarters · filed 2022-05-11 | $10.33M derived: sum of 3 quarters · filed 2022-05-11 | $13.65M derived: sum of 4 quarters · filed 2022-05-11 | ||||||
| 2020-12-31 | $1.79M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $6.22M derived: sum of 2 quarters · filed 2022-03-24 | $9.55M derived: sum of 3 quarters · filed 2022-03-24 | $12.76M 10-K · filed 2022-03-24 | ||||||
| 2020-09-30 | $4.43M 10-Q · filed 2021-11-10 | $7.76M derived: sum of 2 quarters · filed 2021-11-10 | $10.97M 10-Q · filed 2021-11-10 | $14.17M derived: sum of 4 quarters · filed 2021-11-10 | ||||||
| 2020-06-30 | $3.33M 10-Q · filed 2021-08-11 | $6.54M 10-Q · filed 2021-08-11 | $9.73M derived: sum of 3 quarters · filed 2021-08-11 | $12.52M derived: sum of 4 quarters · filed 2021-08-11 | ||||||
| 2020-03-31 | $3.21M 10-Q · filed 2021-05-12 | $6.40M derived: sum of 2 quarters · filed 2021-05-12 | $9.19M derived: sum of 3 quarters · filed 2021-05-12 | $11.29M derived: sum of 4 quarters · filed 2021-05-12 | ||||||
| 2019-12-31 | $3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | $5.98M derived: sum of 2 quarters · filed 2021-03-24 | $8.08M derived: sum of 3 quarters · filed 2021-03-24 | $11.01M 10-K · filed 2021-03-24 | ||||||
| 2019-09-30 | $2.79M 10-Q · filed 2020-11-12 | $4.88M derived: sum of 2 quarters · filed 2020-11-12 | $7.82M 10-Q · filed 2020-11-12 | $10.74M derived: sum of 4 quarters · filed 2020-11-12 | ||||||
| 2019-06-30 | $2.10M 10-Q · filed 2020-08-12 | $5.03M 10-Q · filed 2020-08-12 | $7.96M derived: sum of 3 quarters · filed 2020-08-12 | $9.29M derived: sum of 4 quarters · filed 2020-08-12 | ||||||
| 2019-03-31 | $2.93M 10-Q · filed 2020-05-11 | $5.86M derived: sum of 2 quarters · filed 2020-05-11 | $7.19M derived: sum of 3 quarters · filed 2020-05-11 | $11.42M derived: sum of 4 quarters · filed 2020-05-11 | ||||||
| 2018-12-31 | $2.93M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | $4.26M derived: sum of 2 quarters · filed 2020-03-19 | $8.49M derived: sum of 3 quarters · filed 2020-03-19 | $9.73M 10-K · filed 2020-03-19 | ||||||
| 2018-09-30 | $1.33M 10-Q · filed 2019-11-12 | $5.56M derived: sum of 2 quarters · filed 2019-11-12 | $6.80M 10-Q · filed 2019-11-12 | $9.09M derived: sum of 4 quarters · filed 2019-11-12 | ||||||
| 2018-06-30 | $4.23M 10-Q · filed 2019-08-16 | $5.47M 10-Q · filed 2019-08-16 | $7.75M derived: sum of 3 quarters · filed 2019-08-16 | $8.81M derived: sum of 4 quarters · filed 2019-08-16 | ||||||
| 2018-03-31 | $1.24M 10-Q · filed 2019-05-13 | $3.52M derived: sum of 2 quarters · filed 2019-05-13 | $4.58M derived: sum of 3 quarters · filed 2019-05-13 | $5.10M derived: sum of 4 quarters · filed 2019-05-13 | ||||||
| 2017-12-31 | $2.29M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21 | $3.35M derived: sum of 2 quarters · filed 2019-02-21 | $3.86M derived: sum of 3 quarters · filed 2019-02-21 | $4.54M 10-K · filed 2019-02-21 | ||||||
| 2017-09-30 | $1.06M 10-Q · filed 2018-11-13 | $1.58M derived: sum of 2 quarters · filed 2018-11-13 | $2.26M 10-Q · filed 2018-11-13 | $3.14M derived: sum of 4 quarters · filed 2018-11-13 | ||||||
| 2017-06-30 | $515.00K 10-Q · filed 2018-08-10 | $1.20M 10-Q · filed 2018-08-10 | $2.08M derived: sum of 3 quarters · filed 2018-08-10 | $2.58M derived: sum of 4 quarters · filed 2018-08-10 | ||||||
| 2017-03-31 | $683.00K 10-Q · filed 2018-05-14 | $1.56M derived: sum of 2 quarters · filed 2018-05-14 | $2.06M derived: sum of 3 quarters · filed 2018-05-14 | $2.17M derived: sum of 4 quarters · filed 2018-05-14 | ||||||
| 2016-12-31 | $880.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-28 | $1.38M derived: sum of 2 quarters · filed 2018-03-28 | $1.48M derived: sum of 3 quarters · filed 2018-03-28 | $1.50M 10-K · filed 2018-03-28 | $1.50M 10-K · filed 2017-04-03 | |||||
| 2016-09-30 | $497.00K 10-Q · filed 2017-11-13 | $496.66K 10-Q · filed 2016-11-21 | $602.00K derived: sum of 2 quarters · filed 2017-11-13 | $616.00K 10-Q · filed 2017-11-13 | $616.50K 10-Q · filed 2016-11-21 | |||||
| 2016-06-30 | $105.00K 10-Q · filed 2017-08-11 | $361.73K 10-Q · filed 2016-08-15 | $120.00K 10-Q · filed 2017-08-11 | $376.73K 10-Q · filed 2016-08-15 | ||||||
| 2016-03-31 | $15.00K 10-Q · filed 2017-05-12 | |||||||||
| 2015-12-31 | $260.42K 10-K · filed 2017-04-03 | |||||||||
| 2015-09-30 | $38.41K 10-Q · filed 2016-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |